Titan Pharmaceuticals Share Price

TTNP

US8883147055

Market Closed - Nasdaq 21:00:00 14/09/2026 BST			5-day change	1st Jan Change
0.3800 ^USD	+4.54%		-13.51%	-91.76%

03/10/25	Titan Pharmaceuticals announces closing of merger with Black Titan Corporation	RE
01/10/25	Titan Pharmaceuticals, Inc. Appoints Chay Weei Jye as the Sole Director and Acting Secretary, Effective October 1, 2025	CI

Valuation: Titan Pharmaceuticals

Market Cap	6.13M 5.31M 5.01M 4.54M 8.52M 586M 8.59M 59.77M 23.02M 298M 23.03M 22.52M 946M	P/E 2023	-1.11x	P/E 2024	-0.62x
Enterprise Value	3.3M 2.86M 2.7M 2.45M 4.59M 315M 4.62M 32.18M 12.39M 161M 12.4M 12.12M 510M	EV / Sales 2023	0.11x	EV / Sales 2024	-
Free-Float	-	Yield 2023 *	-	Yield 2024	-

* Estimated data More valuation ratios

Latest news: Titan Pharmaceuticals

03/10/25	Titan Pharmaceuticals announces closing of merger with Black Titan Corporation	RE
01/10/25	Titan Pharmaceuticals, Inc. Appoints Chay Weei Jye as the Sole Director and Acting Secretary, Effective October 1, 2025	CI
30/09/25	Titan Pharmaceuticals, Inc.(NasdaqCM:TTNP) dropped from NASDAQ Composite Index	CI
30/09/25	Ke Sdn. Bhd. completed the acquisition of Titan Pharmaceuticals, Inc. in a reverse merger transaction.	CI
14/08/25	Titan Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
26/06/25	Titan Pharmaceuticals, Inc. announced that it has received $0.6 million in funding from Blue Harbour Asset Management L.L.C	CI
23/06/25	Titan Pharmaceuticals, Inc. announced that it expects to receive $0.6 million in funding from Blue Harbour Asset Management L.L.C	CI
14/05/25	Titan Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
11/04/25	Titan Pharmaceuticals Announces $1 Million Private Placement Of Convertible Preferred Stock	RE
10/04/25	Titan Pharmaceuticals, Inc. announced that it has received $1 million in funding	CI
01/04/25	Titan Pharmaceuticals, Inc. Appoints Gabriel Loh as an Independent Director and Member of the Audit Committee	CI
28/03/25	Titan Pharmaceuticals, Inc. announced that it expects to receive $1 million in funding	CI
20/03/25	Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

More news

Analysts' recommendations: Titan Pharmaceuticals

26/05/22	Maxim Downgrades Titan Pharmaceuticals to Hold From Buy	MT
18/02/21	Titan Pharmaceuticals : Maxim Group Upgrades Titan Pharmaceuticals to Buy From Hold, $11 Price Target	MT

More recommendations

Press Releases: Titan Pharmaceuticals

14/08/25	Titan Pharmaceuticals: Q2 Earnings Snapshot	AQ
06/08/25	TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNP	BU
27/06/25	Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock	AQ
03/06/25	Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.	AQ
14/05/25	Titan Pharmaceuticals: Q1 Earnings Snapshot	AQ

More press releases

Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.

Employees

Sector

More about the company

Quotes

Date	Price	Change	Volume
14/09/26	US$0.3800	+4.54%	130,731
11/09/26	US$0.3635	-0.87%	70,031
10/09/26	US$0.3667	-5.95%	138,109
09/09/26	US$0.3899	-2.62%	80,410
08/09/26	US$0.4004	-4.73%	80,749

Delayed Quote Nasdaq

More quotes

1 year	0.36	4.8
3 years	0	14.8
5 years	0	42.2
10 years	0	23,040.03

	2023	2024
Net sales	184K 159K 150K 136K 256K 17.58M 258K 1.79M 691K 8.95M 691K 676K 28.4M	-
Net income	-5.57M -4.82M -4.55M -4.13M -7.74M -532M -7.8M -54.28M -20.9M -271M -20.91M -20.45M -859M	-4.71M -4.07M -3.84M -3.49M -6.54M -450M -6.59M -45.87M -17.66M -229M -17.67M -17.28M -726M
Net Debt	-6.2M -5.36M -5.06M -4.59M -8.61M -592M -8.68M -60.38M -23.25M -301M -23.27M -22.75M -956M	-2.83M -2.45M -2.31M -2.1M -3.94M -270M -3.96M -27.59M -10.63M -138M -10.63M -10.4M -437M

Titan Pharmaceuticals Share Price

Stocks

TTNP

US8883147055

Valuation: Titan Pharmaceuticals

Chart: Titan Pharmaceuticals

Latest news: Titan Pharmaceuticals

Analysts' recommendations: Titan Pharmaceuticals

Press Releases: Titan Pharmaceuticals

Quotes and Performance

Price Extremes

Financials

Company Profile

Quotes

1 day	+4.54%
Current month	-91.76%
Current year	-91.76%